Premium
Scleromyxoedema: treatment of cutaneous and systemic manifestations with high‐dose intravenous immunoglobulin
Author(s) -
Kulczycki A.,
Nelson M.,
Eisen A.,
Heffernan M.
Publication year - 2003
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2003.05682.x
Subject(s) - medicine , dysphagia , dermatology , systemic disease , disease , antibody , scleroderma (fungus) , immunoglobulin a , immunoglobulin g , pathology , immunology , surgery , inoculation
Summary Scleromyxoedema is a rare disease characterized by cutaneous sclerosis, mucin deposition and paraproteinaemia. Internal disease is common, particularly musculoskeletal, gastrointestinal and central nervous system involvement. We report a series of three consecutive patients with scleromyxoedema treated with high‐dose intravenous immunoglobulin (hdIVIg). Each of the three patients had relatively low levels of a highly basic IgG‐λ paraprotein, and each has demonstrated a sustained response of both their cutaneous and extracutaneous disease to hdIVIg. As all patients had perioral skin involvement and microstomia, one measure of cutaneous improvement was the increase in intraincisor distance. Extracutaneous manifestations of scleromyxoedema that improved included ureteral stricture, vocal strength and dysphagia.